Dear John,

Join us for a live taping of A Health Podyssey on March 12 with Yashaswini Singh about her upcoming paper in the March 2025 edition of Health Affairs and takes questions from a live audience.

This event is free for all.

As COVID-19 surged across the US starting in 2020, so too did the use of repurposed medications such as hydroxychloroquine and ivermectin to treat COVID-19 infections.

In an ahead-of-print article published this week, Michelle S. Rockwell and coauthors explore demographic variation in COVID-19-associated outpatient hydroxychloroquine and ivermectin use and spending throughout the public health emergency.

Don Metz To Serve As Interim Editor-In-Chief

This week, we announced that our executive editor Don Metz will be serving as the interim Editor-in-Chief of Health Affairs.

Going forward, Don will continue to manage the organization’s daily operations, support its full-time staff, and plan for the future.

He will also help guide the organization’s senior leadership team in prioritizing the search for a permanent Editor-in-Chief.

Health Affairs is pleased to issue a call for submissions to the new Forefront series, “Health Policy At A Crossroads,” focused on salient health policy developments and debates as President Trump and the new Congress begin their terms.

A Health Podyssey: J. Michael McWilliams on the Effects of Patient Survey Data on Risk Adjustment

Health Affairs' Senior Deputy Editor Rob Lott interviews J. Michael McWilliams of Harvard Medical School and Brigham and Women's Hospital on his recent paper that explores opportunities for the use of patient health survey data for risk adjustment to limit distortionary coding incentives in Medicare.

Health Affairs This Week: BREAKDOWN: Health Care Private Equity Federal Reports

Health Affairs' Jeff Byers welcomes Senior Editor Kathleen Haddad back to the program to discuss two recent reports exploring the impacts of private equity on the US health care system.

Commercial Health Insurance: Spiraling Costs And Growing Dissatisfaction

Richard F. Averill and Michael J. Kalison

Reflections On Caregiving Policy: Progress, Challenges, And Opportunities

Alison Barkoff

Prioritize Prior Authorization Reforms In Medicare Advantage

Molly T. Turco and Meena Seshamani

Harnessing The Power Of Health Data To Combat Gun Violence

Chethan Sathya and Cristian Liu

Medicare’s Drug Price Negotiation And Innovation: What’s Off The Table Matters Too

Feng Xie and Brittany Humphries

Protecting Newborns From RSV: Opening A Reimbursement Pathway

Richard Hughes IV et al.

New Drugs at the Medicare Negotiating Table with Stacie Dusetzina

Join Health Affairs on Tuesday, February 25 for an exclusive Insider virtual event exploring HHS’s announcement of the 15 additional drugs selected for Medicare drug price negotiations, including weight-loss drugs such as Ozempic and Wegovy.

Stacie Dusetzina of Vanderbilt University Medical Center and Health Affairs Insider newsletter writer joins Health Affairs’ Laura Tollen to get Insiders up to speed on this round of drugs, the negotiation process to come, and what to expect in the second Trump administration.